Latest News

New set of rules soon on Orphan drugs, trials | Published: 27th February 2019 | Posted Date: Wednesday 27th February 2019 02:49 AM

India, which first issued a set of guidelines for biosimilars back in 2012, will revise the guidelines again to include orphan drugs and reduce the time needed for approval of clinical trials.

Hyderabad: In a bid to speed up the approval process and accessibility of drugs in the country, the Union government plans to introduce a new set of rules in the coming few weeks, according to an official of the Central Drugs Standard Control Organisation (CDSCO).

India, which first issued a set of guidelines for biosimilars back in 2012, will revise the guidelines again to include orphan drugs and reduce the time needed for approval of clinical trials.

“The new rules, which will substitute the existing rules, have several amendments and are expected in a few weeks,” Ranga Chandrashekar, Deputy Drugs Controller (India), CDSCO, told reporters at the sidelines of the BioAsia expo here in Hyderabad.

Mr Ranga added, “One of the amendments is in regard to the orphan drugs. Previously, there was no definition of orphan drugs. The new rules will define orphan drugs and create a clear, transparent regulatory pathway for approval of orphan drugs. It will also allow approval of drugs with limited data.”

Orphan drugs are medicinal products intended for diagnosis, prevention or treatment of life-threatening or very serious diseases that are rare.

These drugs are called “orphan” because under normal market conditions the pharmaceutical industry has little interest in developing and marketing such products as these are intended for a small number of patients.

In the United States, any disease that has less than 2.5 lakh patients is classified as orphan. Thanks to India's population, the new rules may set the bar as high as 5 lakh.

Despite orphan drugs being a good business opportunity for Indian companies, they tend to avoid manufacturing them, as it does not make sense for them to run the costly clinical trials for such a small number of patients.

Mr Chandrashekar said companies developing orphan drugs could get partial and full waiver of clinical trials, depending on the drug.

“There will be abridged pathway to approve orphan drugs that reduces the cost and time for the drug to reach the market at affordable cost," he said.

The new rules, to cut costs, will allow drugs that are already approved in well-regulated regions such as in the US or Europe to improve accessibility. However, Mr Chandrashekar was quick to remind that Indian companies must adhere to the intellectual property rights.

The rules will also cut down on the time period for approval of clinical trials. Mr Chandrashekar said, “The timeline will be fixed in the new rules. If the regulator fails to provide the necessary approval within the fixed period, it will be deemed approved for clinical trials. Currently, it takes about four months for the process. According to the new rules, if the drug is discovered in India, it will be given approval in 45 days. For others, it'll be 90 days.” At present, such approval takes 120 days.




Kavitha unable to reap benefits of K Chandrasekhar Rao’s effort

BJP candidate D. Arvind, son of TRS Rajya Sabha member D. Srinivas, defeated Ms Kavitha by 80,895 votes.

ls shock for TRS, gets only 9 seats out of 17

Nama Nageswara Rao won Khammam for the TRS against Ms Renuka Chowdary of the Congress with the majority of 1,68,062 votes.

Hyderabad: Ministers’ family members lose big

Labour minister Ch. Malla Reddy’s son-in-law Marri Rajasekhar Reddy, again a fresh face, lost to TPCC working president A Revanth Reddy.

TRS, Congress do enough to halt BJP wave in state

Cadres celebrate BJP’s unexpected performance in Telangana.

TRS will review losses, says K T Rama Rao

Rama Rao congratulated Modi for being elected as the PM for the second time.

Muslims to get alienated: Asaduddin Owaisi

The MIM chief asked how many Muslim candidates won from the BJP.

Hyderabad: Slender win for 4 candidates

In Zaheerabad, the TRS’s B.B. Patil won by 6,229 votes or 0.60 per cent votes against the Congress’s E. Madan Mohan Rao.

Beaten in polls, Chandrababu Naidu now faces three rivals

In recent times, Mr Naidu has distanced himself from several political parties and bureaucrats.

Andhra result: Jagan’s right-hand man to play key role in government

Mr V. Vijaya Sai Reddy is considered as Mr Jagan Mohan Reddy’s man Friday.

Hyderabad: Parties get a different treatment for Lok Sabha polls

This trend was more starkly visible in Odisha where the Biju Janata Dal retained power for an unprecedented fourth term.

BJP victory makes fight for SCS much tougher

The BJP had sought YSRC support in the event of falling short of majority to form government at the Centre.

Hyderabad: 1 woman to represent Telangana in Lok Sabha

2014, too, the state had only one woman MP: Ms Kavitha.

comments powered by Disqus